APA (7th ed.) Citation

Bender, D., Sill, M. W., Lankes, H. A., Reyes, H. D., Darus, C. J., Delmore, J. E., . . . Leslie, K. K. (2015). A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 138(3), 507. https://doi.org/10.1016/j.ygyno.2015.07.018

Chicago Style (17th ed.) Citation

Bender, David, et al. "A Phase II Evaluation of Cediranib in the Treatment of Recurrent or Persistent Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study." Gynecologic Oncology 138, no. 3 (2015): 507. https://doi.org/10.1016/j.ygyno.2015.07.018.

MLA (9th ed.) Citation

Bender, David, et al. "A Phase II Evaluation of Cediranib in the Treatment of Recurrent or Persistent Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study." Gynecologic Oncology, vol. 138, no. 3, 2015, p. 507, https://doi.org/10.1016/j.ygyno.2015.07.018.